双腔起搏联合闭环刺激在倾斜试验诱发的血管迷走性心脏抑制型反射性晕厥中的获益(BIOSync试验):一项随机对照试验的研究方案
BIOSync研究为多中心、患者与结局评估者盲、随机平行对照、安慰剂对照试验,评估双腔起搏对频繁复发、倾斜试验呈VASIS 2B反应(>3秒停搏)的反射性晕厥患者的临床获益。128例患者按1:1随机分配至起搏开启或关闭,随访至首次裁定主要终点事件,最长2年。主要终点为首次晕厥复发时间,次要终点为前驱晕厥或晕厥复合终点。
要点
- ESC对倾斜试验心脏抑制型反射性晕厥起搏植入为IIb类适应证并建议进一步研究。
- 研究纳入倾斜试验呈VASIS 2B反应(>3秒停搏)的频繁复发反射性晕厥患者128例。
- 主要终点为首次晕厥复发时间,设计检出2年晕厥复发相对降低40%、统计效能80%。
核心结论
- BIOSync研究旨在明确评估起搏对倾斜试验呈心脏抑制型反应的反射性晕厥患者的安慰剂对照获益。
研究设计与样本
- 多中心、患者与结局评估者盲、随机平行臂、安慰剂对照试验,128例同意患者按1:1随机分配至双腔起搏开启或关闭,起搏植入后随访至首次裁定主要终点事件,最长2年。
主要发现
- 主要终点为首次植入后晕厥复发时间,次要终点为前驱晕厥或晕厥的复合终点。
- 研究活性组采用双腔起搏基础上的闭环刺激功能。
- 患者至少每3个月通过自填问卷向独立裁定委员会自我报告晕厥症状。
- 研究设计检出2年晕厥复发发生率相对降低40%,统计效能80%。
关键数值与推荐
- ESC对倾斜试验心脏抑制型反射性晕厥人群的起搏器植入给出IIb类适应证,并建议进一步研究。
- 纳入标准包括频繁复发反射性晕厥,疑似(但未证实)由停搏触发,倾斜试验呈VASIS 2B反应(>3秒停搏,不论血压下降)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of dual-chamber cardiac pacing in neuro-mediated reflex syncope with a cardio-inhibitory response to the Tilt-Table test (TT) has not been definitively assessed so far. The lack of reproducibility of results from previous studies may be partially explained by discrepancies in subject selection and some weaknesses in design and methods. The European Society of Cardiology (ESC) has set a class IIb indication to pacemaker implantation in this population recommending further research. METHODS/DESIGN: The BIOSync study is a multicenter, patient- and outcome-assessor-blind, randomized, parallel-arm, placebo-controlled trial with the objective of assessing the clinical benefit of cardiac pacing in patients with frequently recurrent reflex syncope, suspected (but not proven) to be triggered by asystolic pauses as showing a VASIS 2B response to the TT (>3-s pause regardless of blood pressure drop). The primary and secondary endpoints are time to first post-implantation recurrence of syncope or the combination of pre-syncope or syncope, respectively. One hundred and twenty-eight consenting patients will be 1:1 randomized to dual-chamber cardiac pacing 'on' or 'off' after pacemaker implantation, and followed up until the first adjudicated primary endpoint event for a maximum of 2 years. The so-called Closed Loop Stimulation function on top of dual-chamber pacing is the pacing mode selected in the study active arm. Participating patients are asked to self-report syncopal symptoms at least every 3 months with self-administered questionnaires addressed to an independent Adjudication Committee. Patients and members of the Adjudicating Committee are blinded to randomization. The study is designed to detect a 40% relative reduction in the 2-year incidence of syncopal recurrences with 80% statistical power. DISCUSSION: The BIOSync study is designed to definitively assess the benefit of pacing against placebo in reflex syncope patients with a cardio-inhibitory response to the TT. The study will also provide important information on the efficiency of the TT in appropriately selecting reflex syncope patients for cardiac pacing. TRIAL REGISTRATION: ClinicalTrials.gov, identifier: NCT02324920 (27 October 2016, date last accessed).
引用
- Brignole M, Tomaino M, Aerts A, et al. Benefit of dual-chamber pacing with Closed Loop Stimulation in tilt-induced cardio-inhibitory reflex syncope (BIOSync trial): study protocol for a randomized controlled trial. Trials. 2017. PMID: 28472974. doi:10.1186/s13063-017-1941-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。